K. N. Manola, Cytogenetics of pediatric acute myeloid leukemia, Eur J Haematol, vol.83, issue.5, pp.391-405, 2009.

I. Luquet, A. Bidet, W. Cuccuini, M. Lafage-pochitaloff, M. Mozziconacci et al., Place de la cytoge?ne?tique dans la prise en charge des leuce?mies aiguës mye?loïdes : actualisation par le Groupe francophone de cytogénétique hématologique (GFCH), Ann Biol Clin (Paris). 1 sept, vol.74, issue.5, pp.535-581, 2016.

F. Lo-coco, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N Engl J Med. 11 juill, vol.369, issue.2, pp.111-132, 2013.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.19, issue.20, pp.2391-405, 2016.

P. Montesinos and M. A. Sanz, The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the

. Literature, Mediterr J Hematol Infect Dis, vol.4, issue.2011

. Disponible,

S. Kayser, R. F. Schlenk, and U. Platzbecker, Management of patients with acute promyelocytic leukemia, Leukemia. juin, vol.32, issue.6, pp.1277-94, 2018.

U. Creutzig, M. N. Dworzak, K. Bochennek, J. Faber, C. Flotho et al., First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer, vol.64, 2017.

A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona et al., GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children, Blood. 15 juill, vol.106, issue.2, pp.447-53, 2005.

J. J. Ortega, L. Madero, G. Martín, A. Verdeguer, P. García et al., Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.30, pp.7632-7672, 2005.

V. I. References,

J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood. 30 juill, vol.114, issue.5, pp.937-51, 2009.

M. F. Fey, M. Dreyling, . Esmo-guidelines-working, and . Group, Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. mai, vol.21, issue.5, pp.158-161, 2010.

M. Baudard, J. P. Marie, M. Cadiou, F. Viguié, and R. Zittoun, Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients, Br J Haematol. janv, vol.86, issue.1, pp.82-91, 1994.

J. Clavel and . Taux-d'incidence-de, , 2010.

. Disponible,

J. G. Gurney, R. K. Severson, S. Davis, and L. L. Robison, Incidence of cancer in children in the

, Sex-, race-, and 1-year age-specific rates by histologic type, Cancer. 15 avr, vol.75, issue.8, pp.2186-95, 1995.

. ). Stevens-(mrcpath, J. S. Lowe, . Human, and . Histology, , 2005.

B. Royer and M. Arock, Utilisations thérapeutiques des facteurs de croissance hématopoïétiques. I. Erythropoïétine et thrombopoïétine, Ann Biol Clin (Paris). 26 mars, vol.56, issue.2, pp.143-52, 1998.

F. Féger and W. Vainchenker, Hématopoïèse et facteurs de croissance, pp.13-16906

. Disponible,

A. L. Kierszenbaum, Histologie et biologie cellulaire: Une introduction à l'anatomie pathologique. De Boeck Supérieur, vol.648, 2006.

H. Dombret, Utilisation des facteurs de croissance hématopoïétiques: guide pratique

J. L. Eurotext, , 1996.

K. J. Hope, J. L. Dick, and J. E. , Acute myeloid leukemia originates from a hierarchy of

D. G. Gilliland, C. T. Jordan, and C. A. Felix, The molecular basis of leukemia, Hematol Am Soc Hematol Educ Program, pp.80-97, 2004.

P. A. Buffler, M. L. Kwan, P. Reynolds, and K. Y. Urayama, Environmental and genetic risk factors for childhood leukemia: appraising the evidence, Cancer Invest, vol.23, issue.1, pp.60-75, 2005.

L. Kinlen, Evidence for an infective cause of childhood leukaemia: comparison of a Scottish new town with nuclear reprocessing sites in Britain. The Lancet, vol.10, pp.1323-1330, 1988.

M. Greaves, Infection, immune responses and the aetiology of childhood leukaemia

, Nat Rev Cancer. mars, vol.6, issue.3, pp.193-203, 2006.

M. Greaves and P. A. Buffler, Infections in early life and risk of childhood ALL, Br J Cancer. 10 mars, vol.100, issue.5, p.863, 2009.

J. Rudant, L. Orsi, F. Menegaux, A. Petit, A. Baruchel et al., Childhood acute leukemia, early common infections, and allergy: The ESCALE Study, Am J Epidemiol, vol.172, issue.9, pp.1015-1042, 2010.

K. Y. Urayama, X. Ma, S. Selvin, C. Metayer, A. P. Chokkalingam et al.,

, Early life exposure to infections and risk of childhood acute lymphoblastic leukemia, Int J Cancer. 1 avr, vol.128, issue.7, pp.1632-1675, 2011.

M. Belson, B. Kingsley, and A. Holmes, Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect, janv, vol.115, issue.1, pp.138-183, 2007.

M. C. Turner, D. T. Wigle, and D. Krewski, Residential Pesticides and Childhood Leukemia

, A Systematic Review and Meta-Analysis. Environ Health Perspect. janv, vol.118, issue.1, pp.33-41, 2010.

J. Rudant, F. Menegaux, G. Leverger, A. Baruchel, B. Nelken et al.,

, Household exposure to pesticides and risk of childhood hematopoietic malignancies: The ESCALE study (SFCE). Environ Health Perspect, déc, vol.115, issue.12, pp.1787-93, 2007.

F. M. Carlos-wallace, L. Zhang, M. T. Smith, G. Rader, C. Steinmaus et al., Utero, and Early-Life Exposure to Benzene and the Risk of Childhood Leukemia: A Meta-Analysis

, Am J Epidemiol. 1 janv, vol.183, issue.1, pp.1-14, 2016.

A. Amigou, C. Sermage-faure, L. Orsi, G. Leverger, A. Baruchel et al., Road Traffic and Childhood Leukemia: The ESCALE Study (SFCE), Environ Health Perspect. avr, vol.119, issue.4, pp.566-72, 2011.

F. Marquant, S. Goujon, L. Faure, S. Guissou, L. Orsi et al., Risk of Childhood Cancer and Socio-economic Disparities: Results of the French Nationwide Study Geocap, Paediatr Perinat Epidemiol, vol.30, issue.6, pp.612-634, 2002.

L. Orsi, J. Rudant, R. Ajrouche, G. Leverger, A. Baruchel et al., Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy, and childhood acute leukemia: the ESTELLE study, Cancer Causes Control CCC. juill, vol.26, issue.7, pp.1003-1020, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01175534

B. Lowenberg, J. R. Downing, and A. Burnett, Acute Myeloid Leukemia, N Engl J Med, vol.30
URL : https://hal.archives-ouvertes.fr/hal-02143595

, sept, vol.341, issue.14, pp.1051-62, 1999.

H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Büchner et al.,

, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood. 21 janv, vol.115, issue.3, pp.453-74, 2010.

J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton et al.,

, Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group, Br J Haematol. août, vol.33, issue.4, pp.451-459, 1976.

J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton et al.,

, Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group, Ann Intern Med. oct, vol.103, issue.4, pp.620-625, 1985.

N. L. Harris, E. S. Jaffe, J. Diebold, G. Flandrin, H. K. Muller-hermelink et al.,

, The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues, Ann Oncol Off J Eur Soc Med Oncol. déc, vol.10, issue.12, pp.1419-1451, 1997.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.19, issue.20, pp.2391-405, 2016.

. Disponible,

M. E. Huang, Y. C. Ye, S. R. Chen, J. R. Chai, J. X. Lu et al., Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood. août, vol.72, issue.2, pp.567-72, 1988.

C. Chomienne, P. Ballerini, N. Balitrand, M. T. Daniel, P. Fenaux et al., Alltrans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship, Blood, vol.76, issue.9, pp.1710-1717, 1990.

D. L. , Histoire(s) de la leucémie aiguë, Rev Prat, vol.65, p.5, 2015.

S. L. Soignet, S. R. Frankel, D. Douer, M. S. Tallman, H. Kantarjian et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 15 sept, vol.19, issue.18, pp.3852-60, 2001.

F. Lo-coco, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

, Engl J Med. 11 juill, vol.369, issue.2, pp.111-132, 2013.

C. Niu, H. Yan, T. Yu, H. P. Sun, J. X. Liu et al., Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.15, issue.10, pp.3315-3339, 1999.

O. Abla, M. A. Kutny, A. M. Testi, J. H. Feusner, U. Creutzig et al., Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel, Br J Haematol, vol.175, issue.4, pp.588-601, 2016.

A. M. Testi, M. Angiò, F. Locatelli, A. Pession, L. Coco et al.,

, APL): Comparison Between Children and Adults, Mediterr J Hematol Infect Dis

L. Zhang and X. Zhu, Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in china, Mediterr J Hematol Infect Dis, vol.4, issue.1, p.2012012, 2012.

H. Wang, L. Hao, X. Wang, J. Li, Q. Wu et al., Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience, Int J Hematol. juin, vol.91, issue.5, pp.820-825, 2010.

J. Zhou, Y. Zhang, J. Li, X. Li, J. Hou et al., Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia, Blood. 4 mars, vol.115, issue.9, pp.1697-702, 2010.

L. Zhang, X. Zhu, Y. Zou, Y. Chen, and X. Chen, Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China, Int J Hematol. févr, vol.93, issue.2, pp.199-205, 2011.

Y. Cheng, L. Zhang, J. Wu, A. Lu, B. Wang et al., Long-term prognosis of childhood

V. Lallemand-breitenbach, J. Zhu, and H. De-thé, La leuce?mie aiguë promylocytaire : un paradigme des traitements cible?s sur l'oncogène ?, MS Me?decine Sci Rev Pap ISSN, p.767
DOI : 10.4267/10608/1783

. Disponible,

A. M. Ishov, A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff et al.,

, PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1, J Cell Biol, vol.147, issue.2, pp.221-255, 1999.

F. Quignon, D. Bels, F. Koken, M. Feunteun, J. Ameisen et al., PML induces a novel caspase-independent death process, Nat Genet, vol.20, issue.3, pp.259-65, 1998.

S. L. Soignet, P. Maslak, Z. G. Wang, S. Jhanwar, E. Calleja et al., Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med, vol.339, pp.1341-1349, 1998.

J. Zhu, M. H. Koken, F. Quignon, M. K. Chelbi-alix, L. Degos et al., Arsenicinduced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia, Proc Natl Acad Sci U S A. 15 avr, vol.94, issue.8, pp.3978-83, 1997.

S. Torii, D. A. Egan, R. A. Evans, and J. C. Reed, Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs), EMBO J, vol.18, issue.21, pp.6037-6086, 1999.
DOI : 10.1093/emboj/18.21.6037

URL : http://emboj.embopress.org/content/18/21/6037.full.pdf

M. Giannì, M. H. Koken, M. K. Chelbi-alix, G. Benoit, M. Lanotte et al.,

, Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells, Blood. 1 juin, vol.91, issue.11, pp.4300-4310, 1998.

S. De-botton, V. Coiteux, S. Chevret, C. Rayon, E. Vilmer et al., Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol. 15 avr, vol.22, issue.8, pp.1404-1416, 2004.

U. Creutzig, M. N. Dworzak, K. Bochennek, J. Faber, C. Flotho et al., First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standardrisk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid

, Pediatr Blood Cancer. août, vol.64, issue.8, 2017.

, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia, survival, vol.15, issue.11, pp.1525-1533, 2016.

V. Mathews, B. George, E. Chendamarai, K. M. Lakshmi, S. Desire et al., Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.28, issue.24, pp.3866-71, 2010.

A. Schumacher, D. Wewers, A. Heinecke, C. Sauerland, O. M. Koch et al.,

, Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia, Leuk Res. avr, vol.26, issue.4, pp.355-62, 2002.

F. Efficace, F. Mandelli, G. Avvisati, F. Cottone, F. Ferrara et al.,

, Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-ofLife Outcomes, J Clin Oncol, vol.32, issue.30, pp.3406-3418, 2014.

Y. Lou, Y. Ma, J. Sun, S. Suo, H. Tong et al., Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia, Ann Hematol, vol.96, issue.11, pp.1793-800, 2017.

A. K. Burnett, N. H. Russell, R. K. Hills, D. Bowen, J. Kell et al., Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, Lancet Oncol, vol.16, issue.13, pp.1295-305, 2015.